WO2004023340A8 - Non-psychotropic cannabinoids for prevention of cognitive impairment - Google Patents

Non-psychotropic cannabinoids for prevention of cognitive impairment Download PDF

Info

Publication number
WO2004023340A8
WO2004023340A8 PCT/IL2003/000604 IL0300604W WO2004023340A8 WO 2004023340 A8 WO2004023340 A8 WO 2004023340A8 IL 0300604 W IL0300604 W IL 0300604W WO 2004023340 A8 WO2004023340 A8 WO 2004023340A8
Authority
WO
WIPO (PCT)
Prior art keywords
cognitive impairment
prevention
certain types
psychotropic cannabinoids
diseases
Prior art date
Application number
PCT/IL2003/000604
Other languages
French (fr)
Other versions
WO2004023340A9 (en
WO2004023340A3 (en
WO2004023340A2 (en
Inventor
Seth Kindler
Aaron Garzon
George Fink
Original Assignee
Pharmos Corp
Seth Kindler
Aaron Garzon
George Fink
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmos Corp, Seth Kindler, Aaron Garzon, George Fink filed Critical Pharmos Corp
Priority to AU2003245023A priority Critical patent/AU2003245023A1/en
Priority to EP03794042A priority patent/EP1545504A2/en
Priority to JP2004534012A priority patent/JP2006502159A/en
Priority to PCT/IL2003/000735 priority patent/WO2004021974A2/en
Priority to AU2003256059A priority patent/AU2003256059A1/en
Priority to CA002497164A priority patent/CA2497164A1/en
Publication of WO2004023340A2 publication Critical patent/WO2004023340A2/en
Publication of WO2004023340A8 publication Critical patent/WO2004023340A8/en
Publication of WO2004023340A9 publication Critical patent/WO2004023340A9/en
Publication of WO2004023340A3 publication Critical patent/WO2004023340A3/en
Priority to IL16680505A priority patent/IL166805A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising as an active ingredient non-psychotropic cannabinoids for preventing, alleviating or diminishing cognitive impairment resulting from certain types of surgery, diseases or viral infections, fetal distress, pre-term or low weight delivery, from medical intervention such as certain types of medication, irradiation or electroconvulsive therapy, or for prophylactic use in populations exhibiting mild cognitive impairment, at risk for chronic neurodegenerative diseases.
PCT/IL2003/000604 2002-09-05 2003-07-23 Non-psychotropic cannabinoids for prevention of cognitive impairment WO2004023340A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2003245023A AU2003245023A1 (en) 2002-09-05 2003-07-23 Non-psychotropic cannabinoids for prevention of cognitive impairment
EP03794042A EP1545504A2 (en) 2002-09-05 2003-09-04 Non-psychotropic cannabinoids for prevention of cognitive impairment
JP2004534012A JP2006502159A (en) 2002-09-05 2003-09-04 Non-psychotropic cannabinoids to prevent cognitive impairment
PCT/IL2003/000735 WO2004021974A2 (en) 2002-09-05 2003-09-04 Non-psychotropic cannabinoids for prevention of cognitive impairment
AU2003256059A AU2003256059A1 (en) 2002-09-05 2003-09-04 Non-psychotropic cannabinoids for prevention of cognitive impairment
CA002497164A CA2497164A1 (en) 2002-09-05 2003-09-04 Non-psychotropic cannabinoids for prevention of cognitive impairment
IL16680505A IL166805A0 (en) 2002-09-05 2005-02-10 Non-psychotropic cannabinoids for prevention of cognitive impairment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40895802P 2002-09-05 2002-09-05
US60/408,958 2002-09-05

Publications (4)

Publication Number Publication Date
WO2004023340A2 WO2004023340A2 (en) 2004-03-18
WO2004023340A8 true WO2004023340A8 (en) 2004-06-10
WO2004023340A9 WO2004023340A9 (en) 2004-07-15
WO2004023340A3 WO2004023340A3 (en) 2004-08-26

Family

ID=31978710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/000604 WO2004023340A2 (en) 2002-09-05 2003-07-23 Non-psychotropic cannabinoids for prevention of cognitive impairment

Country Status (4)

Country Link
EP (1) EP1545504A2 (en)
AU (1) AU2003245023A1 (en)
CA (1) CA2497164A1 (en)
WO (1) WO2004023340A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538993A (en) * 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US6211230B1 (en) * 1999-09-27 2001-04-03 The United States Of America As Represented By The Secretary Of The Army Method of reducing brain damage resulting from seizures
HUP0301628A3 (en) * 2000-06-22 2007-05-29 Pharmos Corp Novel non-psychotropic cannabinoids

Also Published As

Publication number Publication date
AU2003245023A8 (en) 2004-03-29
WO2004023340A9 (en) 2004-07-15
CA2497164A1 (en) 2004-03-18
AU2003245023A1 (en) 2004-03-29
WO2004023340A3 (en) 2004-08-26
EP1545504A2 (en) 2005-06-29
WO2004023340A2 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
TW200718418A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
CA2505128A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
TNSN08079A1 (en) Pharmaceutical compositions for the treatment of inner ear disorders
CA2582289C (en) Inhibition of tumour cell migration
WO2007119098A3 (en) Use of an nmda receptor antagonist the treatment of tinnitus induced by cochlear excitotoxicity
EP2460522A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MX2012007410A (en) Novel antiviral compounds.
WO2005094799A3 (en) Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity
EP1299374A4 (en) Novel non-psychotropic cannabinoids
BRPI0924460A2 (en) pharmaceutical composition for use in medical and veterinary ophthalmology
WO2003097052A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
ES2187300A1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
WO2001076555A3 (en) Lipid-based drug delivery systems for topical application
UA92498C2 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
MX2021010213A (en) Coronavirus therapeutic agent comprising elaeocarpus sylvestris extract as active ingredient.
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
WO2004021974A3 (en) Non-psychotropic cannabinoids for prevention of cognitive impairment
WO2004023340A3 (en) Non-psychotropic cannabinoids for prevention of cognitive impairment
WO2006089120A3 (en) Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
EP1232748A4 (en) Substituted nitrobenzene derivatives as medicines and other useful uses thereof
IL160605A0 (en) Use of c2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity
WO2020222538A3 (en) Composition for prevention or treatment of hair loss including hapln1
WO2003043966A3 (en) Clusianon isomers and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 12/2004 REPLACE "A1" BY "A2" AND UNDER "PUBLISHED", REPLACE "WITH INTERNATIONAL SEARCH REPORT" BY "WITHOUT INTERNATIONAL SEARCH REPORT"

COP Corrected version of pamphlet

Free format text: INTERNATIONAL SEARCH REPORT (3 PAGES) DELETED

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP